Biomarker analysis

To tailor the Gyrolab platform for use in biomarker research, detection limits have been further improved through the development of Bioaffy 1000, processing 1000 nl of sample in each immunoassay. The performance of Bioaffy 1000 has been evaluated for different analytes in human serum and plasma samples.

Serum and plasma samples from blood donors and patients were analyzed with respect to human Tissue Factor (hTF) concentration. Samples were processed in Bioaffy 200 and Bioaffy 1000 respectively. As expected, the concentration levels in most of the samples were too low to enable quantification, i.e. a signal:noise ratio of three or more, using Bioaffy 200 (Figure 1). 

When the same samples were analyzed in Bioaffy 1000 quantifiable results were achieved for 92% of the samples. Similar results were achieved when quantifying MIP-1β. The resulting concentration range of MIP-1β in the serum and plasma samples was 50–900 ng/ml (Figure 2), with a resulting average CV% of 4.3% for triplicate measurements using Bioaffy 1000.